Drug discovery in Cytopathology
The rapid pace of drug discovery and drug development in Cytopathology, oncology, immunology and ophthalmology brings new challenges; the efficient and effective development of new targeted drugs will require more detailed molecular classifications of histologically homogeneous diseases that show heterogeneous clinical outcomes.
Drug discovery involves the identification of screening hits, medicinal chemistry and optimization of those hits to increase the affinity, selectivity (to reduce the potential of side effects), efficacy/potency, metabolic stability (to increase the half-life), and oral bioavailability. Once a compound that fulfills all of these requirements has been identified, it will begin the process of drug development prior to clinical trials. Discovering drugs that may be a commercial success, or a public health success, involves a complex interaction between investors, industry, academia, patent laws, regulatory exclusivity, marketing and the need to balance secrecy with communication. Meanwhile, for disorders whose rarity means that no large commercial success or public health effect can be expected, the orphan drug funding process ensures that people who experience those disorders can have some hope of pharmacotherapeutic advances.
Enhanced accuracy of cell imaging and analysis systems helps in reducing the time and costs involved in the drug discovery process. This is a major factor driving the growth of the cell analysis market. Furthermore, the market is witnessing significant technological innovations and continuous improvements in cell analysis instruments and consumables for applications such as cell identification, cell proliferation, and target toxicity studies. This is another factor propelling the growth of this market. Corporate and government support for the growth of innovative technologies and rising demand for outsourcing of drug discovery services, especially in the Asia-Pacific region, are also the major reasons for the high-growth of this market. Based on cell analysis products, the consumables market commanded the largest share of ~65.5% in 2013. However, the cell analysis instruments market is poised to grow at the highest CAGR from 2013 to 2018.
- Cytopathology in future medicine
- Advancements in diagnosis pathology
- Drug Therapies related to Cytopathology
- DNA microarrays for assay development
- Pharmacogenomics & Pharmacokinetics
- Molecular Modelling
- Drug targeting & Cytopathology in drug development
Related Conference of Drug discovery in Cytopathology
Drug discovery in Cytopathology Conference Speakers